In non-infectious chronic diseases, i.e., metabolic syndrome or diabetes, the use of PPARγ agonists, like TZDs (including rosiglitazone and pioglitazone), showed some effectiveness in parallel to side effects such as increased weight gain, fluid retention, bone loss, congestive heart failure, etc. (50), which led to its discontinuation as was the case of rosiglitazone (51). This evidence concerns the gene PPARG and metabolic syndrome.